Open Scanner

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Curis Inc

CRIS
Current price
11.17 USD -0.29 USD (-2.53%)
Last closed 11.2 USD
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 66 013 696 USD
Yield for 12 month +1 296.25 %
1Y
3Y
5Y
10Y
15Y
CRIS
21.11.2021 - 28.11.2021

Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single arm expansion trial in patients with relapsed or refractory, or R/R, AML and high-risk myelodysplastic syndromes. The company's pipeline also includes Fimepinostat, an oral dual inhibitor of HDAC and PI3K enzymes for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma; CA-170, an oral, small molecule antagonist designated as CA-170 that selectively targets PD-L1 and VISTA; and CA-327, an oral, small molecule, TIM3/PD-L1, which is a molecule antagonist of PD-L1 and TIM3. It has collaboration agreement with Genentech Inc., or Genentech and F. Hoffmann-La Roche Ltd, or Roche, for the commercialization of Erivedge, an orally-administered small molecule hedgehog signaling pathway antagonist for the treatment of advanced basal cell carcinoma, or BCC; Aurigene Discovery Technologies Limited for the discovery, development, and commercialization of small molecule compounds in the areas of immuno-oncology and precision oncology; and also licensed four programs under the Aurigene collaboration, including emavusertib. Curis, Inc. was incorporated in 2000 and is headquartered in Lexington, Massachusetts. Address: Building C, Lexington, MA, United States, 02421

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

22.5 USD

P/E ratio

Dividend Yield

Current Year

+10 023 000 USD

Last Year

+10 162 000 USD

Current Quarter

+2 085 999 USD

Last Quarter

+2 696 000 USD

Current Year

+10 023 000 USD

Last Year

+9 905 000 USD

Current Quarter

+1 620 999 USD

Last Quarter

+2 538 000 USD

Key Figures CRIS

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -48 919 000 USD
Operating Margin TTM -597.75 %
PE Ratio
Return On Assets TTM -39.26 %
PEG Ratio
Return On Equity TTM -207.29 %
Wall Street Target Price 22.5 USD
Revenue TTM 9 812 000 USD
Book Value 1.61 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY -9.2 %
Dividend Yield
Gross Profit TTM -33 372 000 USD
Earnings per share -8.62 USD
Diluted Eps TTM -8.62 USD
Most Recent Quarter I 2024
Quarterly Earnings Growth YOY
Profit Margin

Dividend Analytics CRIS

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History CRIS

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor 1:5
Payout Ratio
Last Split Date 30.05.2018
Dividend Date 30.05.2018

Stock Valuation CRIS

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue 3.6438
Price Sales TTM 8.9855
Enterprise Value EBITDA -0.8091
Price Book MRQ 4.5786

Financials CRIS

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Technical indicators CRIS

For 52 weeks

3.8 USD 18 USD
50 Day MA 13.74 USD
Shares Short Prior Month 67 310
200 Day MA 8.83 USD
Short Ratio 1.91
Shares Short 65 322
Short Percent 1.14 %

Dynamics of changes in the value of assets

Stocks


MSFT

MSFT

430.32 USD Microsoft Corporation +0.69 (+0.16%)
Detailed analytics

ETF funds


S

SX7EEX

14.75 EUR iShares EURO STOXX Banks 30-15 UCITS ETF (DE) 0 (0%)
Detailed analytics

Metals


Gold

2357.98 USD Gold +6.23 (+0.27%)
Detailed analytics